BAXTER INTERNATIONAL INC (BAX) Fundamental Analysis & Valuation

NYSE:BAX • US0718131099

Current stock price

17.63 USD
+0.48 (+2.8%)
At close:
17.7 USD
+0.07 (+0.4%)
After Hours:

This BAX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. BAX Profitability Analysis

1.1 Basic Checks

  • In the past year BAX was profitable.
  • In the past year BAX had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: BAX reported negative net income in multiple years.
  • BAX had a positive operating cash flow in each of the past 5 years.
BAX Yearly Net Income VS EBIT VS OCF VS FCFBAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B -2B 4B

1.2 Ratios

  • BAX's Return On Assets of -4.77% is fine compared to the rest of the industry. BAX outperforms 68.09% of its industry peers.
  • With a decent Return On Equity value of -15.61%, BAX is doing good in the industry, outperforming 62.77% of the companies in the same industry.
  • BAX has a Return On Invested Capital of 1.97%. This is in the better half of the industry: BAX outperforms 69.15% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BAX is significantly below the industry average of 9.15%.
Industry RankSector Rank
ROA -4.77%
ROE -15.61%
ROIC 1.97%
ROA(3y)0.7%
ROA(5y)-0.53%
ROE(3y)2.23%
ROE(5y)-4.18%
ROIC(3y)3.01%
ROIC(5y)3.68%
BAX Yearly ROA, ROE, ROICBAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40

1.3 Margins

  • BAX has a Operating Margin of 3.78%. This is in the better half of the industry: BAX outperforms 69.68% of its industry peers.
  • BAX's Operating Margin has declined in the last couple of years.
  • The Gross Margin of BAX (30.68%) is worse than 73.94% of its industry peers.
  • BAX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 3.78%
PM (TTM) N/A
GM 30.68%
OM growth 3Y-22.24%
OM growth 5Y-24.4%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.08%
GM growth 5Y-5.03%
BAX Yearly Profit, Operating, Gross MarginsBAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. BAX Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BAX is destroying value.
  • BAX has more shares outstanding than it did 1 year ago.
  • BAX has more shares outstanding than it did 5 years ago.
  • BAX has a better debt/assets ratio than last year.
BAX Yearly Shares OutstandingBAX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
BAX Yearly Total Debt VS Total AssetsBAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.2 Solvency

  • BAX has an Altman-Z score of 2.20. This is not the best score and indicates that BAX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • BAX's Altman-Z score of 2.20 is fine compared to the rest of the industry. BAX outperforms 62.23% of its industry peers.
  • BAX has a debt to FCF ratio of 28.54. This is a negative value and a sign of low solvency as BAX would need 28.54 years to pay back of all of its debts.
  • With a decent Debt to FCF ratio value of 28.54, BAX is doing good in the industry, outperforming 66.49% of the companies in the same industry.
  • BAX has a Debt/Equity ratio of 1.55. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of BAX (1.55) is worse than 80.85% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.55
Debt/FCF 28.54
Altman-Z 2.2
ROIC/WACC0.36
WACC5.5%
BAX Yearly LT Debt VS Equity VS FCFBAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • BAX has a Current Ratio of 2.31. This indicates that BAX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of BAX (2.31) is comparable to the rest of the industry.
  • A Quick Ratio of 1.56 indicates that BAX should not have too much problems paying its short term obligations.
  • The Quick ratio of BAX (1.56) is worse than 60.11% of its industry peers.
Industry RankSector Rank
Current Ratio 2.31
Quick Ratio 1.56
BAX Yearly Current Assets VS Current LiabilitesBAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. BAX Growth Analysis

3.1 Past

  • BAX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.24%.
  • BAX shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -5.98% yearly.
  • Looking at the last year, BAX shows a very negative growth in Revenue. The Revenue has decreased by -12.54% in the last year.
  • Measured over the past years, BAX shows a decrease in Revenue. The Revenue has been decreasing by -0.75% on average per year.
EPS 1Y (TTM)-16.24%
EPS 3Y-13.44%
EPS 5Y-5.98%
EPS Q2Q%-24.14%
Revenue 1Y (TTM)-12.54%
Revenue growth 3Y-9.39%
Revenue growth 5Y-0.75%
Sales Q2Q%8.03%

3.2 Future

  • BAX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.15% yearly.
  • BAX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.51% yearly.
EPS Next Y-14.55%
EPS Next 2Y-4.68%
EPS Next 3Y0.24%
EPS Next 5Y9.15%
Revenue Next Year2.39%
Revenue Next 2Y2.34%
Revenue Next 3Y2.46%
Revenue Next 5Y2.51%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BAX Yearly Revenue VS EstimatesBAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 5B 10B 15B
BAX Yearly EPS VS EstimatesBAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

6

4. BAX Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 7.77, the valuation of BAX can be described as very cheap.
  • Based on the Price/Earnings ratio, BAX is valued cheaply inside the industry as 95.21% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 26.86, BAX is valued rather cheaply.
  • BAX is valuated reasonably with a Price/Forward Earnings ratio of 9.09.
  • 95.74% of the companies in the same industry are more expensive than BAX, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 37.39. BAX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 7.77
Fwd PE 9.09
BAX Price Earnings VS Forward Price EarningsBAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BAX indicates a rather cheap valuation: BAX is cheaper than 88.30% of the companies listed in the same industry.
  • 79.79% of the companies in the same industry are more expensive than BAX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 27.41
EV/EBITDA 11.64
BAX Per share dataBAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.68%
EPS Next 3Y0.24%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. BAX Dividend Analysis

5.1 Amount

  • BAX has a yearly dividend return of 0.23%, which is pretty low.
  • BAX's Dividend Yield is rather good when compared to the industry average which is at 0.24. BAX pays more dividend than 89.89% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, BAX's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.23%

5.2 History

  • The dividend of BAX decreases each year by -6.21%.
  • BAX has been paying a dividend for at least 10 years, so it has a reliable track record.
Dividend Growth(5Y)-6.21%
Div Incr Years0
Div Non Decr Years0
BAX Yearly Dividends per shareBAX Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • BAX has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-36.36%
EPS Next 2Y-4.68%
EPS Next 3Y0.24%
BAX Yearly Income VS Free CF VS DividendBAX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B -2B 4B

More info and screens

Find the best dividend stocksShow peers with best dividend

BAX Fundamentals: All Metrics, Ratios and Statistics

BAXTER INTERNATIONAL INC

NYSE:BAX (4/13/2026, 5:05:00 PM)

After market: 17.7 +0.07 (+0.4%)

17.63

+0.48 (+2.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)04-30
Inst Owners109.33%
Inst Owner Change-2.62%
Ins Owners0.18%
Ins Owner Change7.47%
Market Cap9.10B
Revenue(TTM)11.24B
Net Income(TTM)-957.00M
Analysts64.55
Price Target21.95 (24.5%)
Short Float %7.4%
Short Ratio3.69
Dividend
Industry RankSector Rank
Dividend Yield 0.23%
Yearly Dividend0.68
Dividend Growth(5Y)-6.21%
DP-36.36%
Div Incr Years0
Div Non Decr Years0
Ex-Date02-27
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.28%
Min EPS beat(2)-18.72%
Max EPS beat(2)14.16%
EPS beat(4)2
Avg EPS beat(4)0.98%
Min EPS beat(4)-18.72%
Max EPS beat(4)14.16%
EPS beat(8)6
Avg EPS beat(8)3.02%
EPS beat(12)9
Avg EPS beat(12)2.81%
EPS beat(16)10
Avg EPS beat(16)2.49%
Revenue beat(2)1
Avg Revenue beat(2)0.95%
Min Revenue beat(2)-2.38%
Max Revenue beat(2)4.28%
Revenue beat(4)2
Avg Revenue beat(4)0.23%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)4.28%
Revenue beat(8)5
Avg Revenue beat(8)0.31%
Revenue beat(12)7
Avg Revenue beat(12)0.01%
Revenue beat(16)7
Avg Revenue beat(16)-1.2%
PT rev (1m)-1.17%
PT rev (3m)-10.58%
EPS NQ rev (1m)1.77%
EPS NQ rev (3m)-34.22%
EPS NY rev (1m)0.1%
EPS NY rev (3m)-14.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.68%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)0.41%
Valuation
Industry RankSector Rank
PE 7.77
Fwd PE 9.09
P/S 0.81
P/FCF 27.41
P/OCF 10.77
P/B 1.48
P/tB N/A
EV/EBITDA 11.64
EPS(TTM)2.27
EY12.88%
EPS(NY)1.94
Fwd EY11%
FCF(TTM)0.64
FCFY3.65%
OCF(TTM)1.64
OCFY9.28%
SpS21.78
BVpS11.87
TBVpS-6.14
PEG (NY)N/A
PEG (5Y)N/A
Graham Number24.62
Profitability
Industry RankSector Rank
ROA -4.77%
ROE -15.61%
ROCE 2.49%
ROIC 1.97%
ROICexc 2.22%
ROICexgc 5.77%
OM 3.78%
PM (TTM) N/A
GM 30.68%
FCFM 2.95%
ROA(3y)0.7%
ROA(5y)-0.53%
ROE(3y)2.23%
ROE(5y)-4.18%
ROIC(3y)3.01%
ROIC(5y)3.68%
ROICexc(3y)3.41%
ROICexc(5y)4.11%
ROICexgc(3y)9.09%
ROICexgc(5y)11.24%
ROCE(3y)3.97%
ROCE(5y)4.78%
ROICexgc growth 3Y-20.11%
ROICexgc growth 5Y-19.9%
ROICexc growth 3Y-20.01%
ROICexc growth 5Y-27.24%
OM growth 3Y-22.24%
OM growth 5Y-24.4%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.08%
GM growth 5Y-5.03%
F-Score4
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 1.55
Debt/FCF 28.54
Debt/EBITDA 6.74
Cap/Depr 52.29%
Cap/Sales 4.56%
Interest Coverage 1.4
Cash Conversion 60.1%
Profit Quality N/A
Current Ratio 2.31
Quick Ratio 1.56
Altman-Z 2.2
F-Score4
WACC5.5%
ROIC/WACC0.36
Cap/Depr(3y)50.61%
Cap/Depr(5y)56.74%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.24%
EPS 3Y-13.44%
EPS 5Y-5.98%
EPS Q2Q%-24.14%
EPS Next Y-14.55%
EPS Next 2Y-4.68%
EPS Next 3Y0.24%
EPS Next 5Y9.15%
Revenue 1Y (TTM)-12.54%
Revenue growth 3Y-9.39%
Revenue growth 5Y-0.75%
Sales Q2Q%8.03%
Revenue Next Year2.39%
Revenue Next 2Y2.34%
Revenue Next 3Y2.46%
Revenue Next 5Y2.51%
EBIT growth 1Y-55.07%
EBIT growth 3Y-29.54%
EBIT growth 5Y-24.96%
EBIT Next Year37.67%
EBIT Next 3Y12.11%
EBIT Next 5Y17.39%
FCF growth 1Y-42.06%
FCF growth 3Y-14.54%
FCF growth 5Y-22.12%
OCF growth 1Y-17.08%
OCF growth 3Y-11.3%
OCF growth 5Y-14.67%

BAXTER INTERNATIONAL INC / BAX Fundamental Analysis FAQ

What is the fundamental rating for BAX stock?

ChartMill assigns a fundamental rating of 4 / 10 to BAX.


Can you provide the valuation status for BAXTER INTERNATIONAL INC?

ChartMill assigns a valuation rating of 6 / 10 to BAXTER INTERNATIONAL INC (BAX). This can be considered as Fairly Valued.


How profitable is BAXTER INTERNATIONAL INC (BAX) stock?

BAXTER INTERNATIONAL INC (BAX) has a profitability rating of 4 / 10.


What is the valuation of BAXTER INTERNATIONAL INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BAXTER INTERNATIONAL INC (BAX) is 7.77 and the Price/Book (PB) ratio is 1.48.


How financially healthy is BAXTER INTERNATIONAL INC?

The financial health rating of BAXTER INTERNATIONAL INC (BAX) is 4 / 10.